Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can
present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie …

Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Pituitary tumors (PT) are mostly benign, although occasionally they demonstrate aggressive
behavior, invasion of surrounding tissues, rapid growth, resistance to conventional …

Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality,
and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have …

'Pituitary tumours' is an umbrella term for various tumours originating from different regions
of the hypothalamic–pituitary system. The vast majority of pituitary tumours are pituitary …

Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic
hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by …

Aggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary tumors. Their
management is a rapidly evolving field of clinical research and has led pituitary teams to …

Although pituitary neuroendocrine tumors (PitNETs) are usually benign, some are highly
invasive and recurrent. Recurrent PitNETs are often treatment‐resistant and there is …

Background Pituitary adenomas are one type of intracranial tumor, which can be divided into
microadenoma (≤ 1 cm), macroadenoma (> 1 cm), and giant adenoma (≥ 4 cm) according …

A small subset of pituitary adenomas grows despite maximal treatment with standard
therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 …